To study the relationship between ARS2 and clinical outcome in glioma patients, we first analyzed the expression profile of ARS2 in the REMBRANDT (REpository for Molecular BRAin Neoplasia DaTa) database, which included data from 105 patients with astrocytoma, 181 with GBM, and 336 with all forms of glioma. This evidence concerns the gene SRRT and neoplasm.